Valeant Pharmaceuticals: Now Comes the Hard Part

From Stocks To Watch Today
January 11, 2017 - 12:40pm

I've mentioned over and over again that Valeant Pharmaceuticals International (VRX) is likely to need to sell more assets in order to get its debt under control despite yesterday's $2.1 billion in sales. Canaccord Genuity's Neil Maruoka and Matt Bottomley explain why:



Continue reading this article »